Department of Biological Sciences, Idaho State University, Pocatello, ID 83209, USA.
Division of Pulmonary, Allergy, and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Int J Mol Sci. 2021 Oct 12;22(20):10982. doi: 10.3390/ijms222010982.
Exposure to Libby amphibole (LA) asbestos-like fibers is associated with increased risk of asbestosis, mesothelioma, pulmonary disease, and systemic autoimmune disease. LGM2605 is a small molecule antioxidant and free radical scavenger, with anti-inflammatory effects in various disease models. The current study aimed to determine whether the protective effects of LGM2605 persist during the late inflammatory phase post-LA exposure. Male and female C57BL/6 mice were administered daily LGM2605 (100 mg/kg) via gel cups for 3 days before and 14 days after a 200 µg LA given via intraperitoneal (i.p.) injection. Control mice were given unsupplemented gel cups and an equivalent dose of i.p. saline. On day 14 post-LA treatment, peritoneal lavage was assessed for immune cell influx, cytokine concentrations, oxidative stress biomarkers, and immunoglobulins. During the late inflammatory phase post-LA exposure, we noted an alteration in trafficking of both innate and adaptive immune cells, increased pro-inflammatory cytokine concentrations, induction of immunoglobulin isotype switching, and increased oxidized guanine species. LGM2605 countered these changes similarly among male and female mice, ameliorating late inflammation and altering immune responses in late post-LA exposure. These data support possible efficacy of LGM2605 in the prolonged treatment of LA-associated disease and other inflammatory conditions.
暴露于利比角闪石(LA)类石棉纤维与石棉肺、间皮瘤、肺部疾病和系统性自身免疫性疾病的风险增加有关。LGM2605 是一种小分子抗氧化剂和自由基清除剂,在各种疾病模型中具有抗炎作用。本研究旨在确定 LGM2605 的保护作用是否在 LA 暴露后的晚期炎症期持续存在。雄性和雌性 C57BL/6 小鼠在腹腔(i.p.)注射 200µg LA 前 3 天和后 14 天每天通过凝胶杯给予 LGM2605(100mg/kg)。对照小鼠给予未补充凝胶杯和等效剂量的 i.p.生理盐水。在 LA 处理后 14 天,评估腹膜灌洗以评估免疫细胞浸润、细胞因子浓度、氧化应激生物标志物和免疫球蛋白。在 LA 暴露后的晚期炎症期,我们注意到先天和适应性免疫细胞的迁移发生改变,促炎细胞因子浓度增加,免疫球蛋白同种型转换诱导,以及氧化鸟嘌呤物种增加。LGM2605 在雄性和雌性小鼠中同样对抗这些变化,改善晚期炎症并改变晚期 LA 暴露后的免疫反应。这些数据支持 LGM2605 在延长治疗 LA 相关疾病和其他炎症性疾病中的可能疗效。